Diabetes Remission - The Holy Grail in Diabetes Management
Chronicle of Diabetes Research and Practice · 2024
DOI: 10.4103/cdrp.cdrp_15_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chronicle of Diabetes Research and Practice, 2024. Verfasst von Sunder Mudaliar. Die Arbeit nennt 17 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes (T2DM) is a chronic metabolic disease and a major public health burden worldwide. In 2021, per International Diabetes Federation statistics, approximately 537 million adults were living with diabetes.[1] This is expected to increase to 643 million by 2030 and a staggering 783 million by 2045. Unfortunately, 3 in 4 adults with diabetes live in low- and middle-income countries. The hallmark of T2DM is hyperglycemia due to a combination of progressive impairment of beta cell function and worsening insulin resistance. Most patients with T2DM are obese, and obesity is well known to worsen beta cell function and insulin resistance. Long-term hyperglycemia increases the risk of microvascular complications (retinopathy, nephropathy, and neuropathy), accelerates the progression of atherosclerosis, and leads to premature cardiovascular disease with higher rates of myocardial infarctions, heart failure, and strokes.[2] In a recent study in high-income populations, it was estimated that years of life lost to T2DM ranged from 2.5 years to 12.9 years.[3] More alarming is the fact that young-onset T2DM before the age of 40 years is becoming increasingly common.[4] Despite the grim statistics above, the good news is that T2DM can be prevented when discovered in the prediabetes stage. Several large studies have shown the protective effect of intensive lifestyle measures and pharmacologic agents such as metformin, thiazolidinediones, and acarbose in preventing diabetes.[5] However, in the long-term, most individuals with prediabetes progress to develop overt T2DM and need to be treated with anti-diabetic medications to lower HbA1C levels and reduce the risk of microvascular and macrovascular complications. However, the “Holy Grail” in diabetes management has always been a “cure” for T2DM. It is important to note, that numerous terms have been used to describe the regression from overt diabetes to normal glucose regulation. These include resolution, reversal, remission, and cure of diabetes. In 2021, the American Diabetes Association (ADA) issued a consensus report which stated that the most appropriate term to use should be diabetes remission since it strikes a balance between the fact that diabetes may not always be active, while also acknowledging the fact that the improvement in glycemia may not be permanent and frank diabetes may recur.[6] DIABETES REMISSION WITH LIFESTYLE MEASURES The Look AHEAD study was the first large study to document diabetes remission with intensive lifestyle intervention (ILI) in 5145 overweight/obese subjects (mean body mass index [BMI] ~36) with T2DM (Mean HbA1C ~7.4%).[7] Subjects were randomized to ILI and put on a low-calorie diet (1200–1800 Kcal/d) and advised 175 min/week of moderate to intense physical activity. At 1 year, weight loss in the intensive group was 8.6% versus 0.7% in the control group given standard diabetes support and education (DSE). Weight loss was attenuated at 4 years at 4.7% in the ILI group versus 0.8% in the DSE group. As expected, the significant loss in the ILI group was associated with higher rates of partial or complete remission of diabetes (defined as transition from diabetes to a prediabetes or nondiabetic level of glycemia with no antihyperglycemic medication). The absolute rate of continuous, sustained remission for at least 2 years was 9.2% with intensive lifestyle versus 1.7% in the standard group. At 4 years, these rates decreased to 3.5% with intensive lifestyle versus 0.5% in the standard group. It is important to note that the LOOK AHEAD study was primarily designed to examine the effect of weight loss on cardiovascular disease and although this outcome was negative, the exploratory outcome of diabetes remission was positive, albeit modest. Better outcomes were seen in the DiRECT study in the UK which assessed whether intensive weight management within routine primary care increased remission of T2DM in patients diagnosed within the past 6 years and not on insulin.[8] In this open-label, cluster-randomized trial, 306 individuals (mean age ~54 years, BMI ~35, weight ~100 Kg, diabetes duration ~3 years, and HbA1C 7.7%) were randomized to an intervention group that underwent total diet replacement (825–853 kcal/day formula diet for 3–5 months), progressive food reintroduction (2–8 weeks), and structured support for long-term weight loss maintenance, or a control group. Mean body weight decreased by ~10% in the intervention group versus ~1% in the control group. This greater weight loss in the intervention group was associated with diabetes remission (defined as HbA1c
Zitieren
APA
Mudaliar, S. (2024). Diabetes Remission - The Holy Grail in Diabetes Management. Chronicle of Diabetes Research and Practice. https://doi.org/10.4103/cdrp.cdrp_15_23
Vancouver
Mudaliar S. Diabetes Remission - The Holy Grail in Diabetes Management. Chronicle of Diabetes Research and Practice. 2024. doi:10.4103/cdrp.cdrp_15_23
BibTeX
@article{Mudaliar2024,
author = {Mudaliar, Sunder},
title = {Diabetes Remission - The Holy Grail in Diabetes Management},
journal = {Chronicle of Diabetes Research and Practice},
year = {2024},
doi = {10.4103/cdrp.cdrp_15_23}
}
EUVIMED